Immix Biopharma, Inc.
NASDAQ:IMMXBiotechnology
+$0.09 today
- Market cap
- $595.91M
- Beta
- 0.10
- P/E (TTM)
- -10.1
- EPS (TTM)
- -$0.91
Volume 0.88M
Average 1.07M
IMMX Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Immix Biopharma, Inc.NASDAQ: IMMX
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation declines year over year
Q1 FY2026 stock-based compensation of $575.57K fell 33.7% year over year, behind the -27.0% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 0.8% from the prior quarter. Over 3 fiscal years it compounded at +57.6% a year.
Context
- Stock-based compensation increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -33.7% toward the trailing-twelve-month pace of -27.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 2.44M USD
- Year-over-year change
- -19.2%
- 4-year CAGR
- +82.7%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.44M | -19.2% |
| FY2024 | 2024-12-31 | 3.02M | +17.7% |
| FY2023 | 2023-12-31 | 2.57M | +311.1% |
| FY2022 | 2022-12-31 | 624.07K | +185.0% |
| FY2021 | 2021-12-31 | 218.98K | — |
Stock-Based Compensation vs competitors
How IMMX compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -27.0% is the 8th highest of 11, against a peer median of +0.2%.
- Over three fiscal years its annual growth of +57.6% compares with a peer median of -5.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $63M USD | -6.0% | -2.6% | 53.8% | |
| LTM Aug 2026 | $40.66M USD | +8.7% | +10.5% | 5.8% | |
| LTM Sep 2026 | $36.81M USD | -0.7% | — | 32869.6% | |
NBPNovaBridge Biosciences | LTM Sep 2025 | CN¥26.02M CNY | +1.1% | -74.4% | — |
| LTM Mar 2026 | $12.55M USD | -55.6% | -11.3% | 8.0% | |
| LTM Mar 2026 | $11.29M USD | +44.4% | +3.8% | — | |
| LTM Mar 2026 | $9.12M USD | +17.3% | -21.7% | 25.6% | |
| LTM Mar 2026 | $5.99M USD | +19.7% | +10.2% | 1140.6% | |
| LTM Mar 2026 | $2.15M USD | -27.0% | +57.6% | — | |
| FY2025 | A$1.16M AUD | -35.2% | -7.8% | 23.1% | |
| FY2025 | €0 EUR | -100.0% | — | — | |
| Peer median (excluding IMMX) | — | +0.2% | -5.2% | 25.6% | |
Competitors are the stored peer set for IMMX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (24.38M) | (8.23M) | (15.6M) | (21.61M) | (29.44M) |
| Depreciation & Amortization | 2.47K | 2.14K | 5.47K | 115.39K | 364.5K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 218.98K | 624.07K | 2.57M | 3.02M | 2.44M |
| Change in Working Capital | (391.04K) | 195.21K | 1.65M | 3.97M | 2.7M |
| Accounts Receivables | 97.67K | (236.38K) | (893.4K) | (971.53K) | 2.06M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (106.06K) | 1.13M | 2.43M | 4.4M | 1.03M |
| Other Working Capital | (382.64K) | (700.15K) | 111.84K | 537.2K | (384.74K) |
| Other Non-Cash Items | 22.96M | 0 | 0 | 2.94M | 0 |
| Operating Cash Flow | (1.59M) | (7.41M) | (11.37M) | (14.6M) | (23.93M) |
| Capital Expenditures | (802) | 3 | (52.09K) | (1.18M) | (732.93K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | (6.48M) |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (802) | 0 | (52.09K) | (1.18M) | (7.21M) |
| Debt Repayment | 200K | (50K) | 0 | 0 | 0 |
| Common Stock Issued | 18.65M | 3.39M | 15.7M | 15.95M | 107.39M |
| Common Stock Repurchased | 0 | (99.96K) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (6.72K) | (232K) | 0 | 0 |
| Financing Cash Flow | 18.85M | 3.23M | 15.46M | 15.95M | 107.39M |
| Effect of Forex Changes | (5.43K) | (31.52K) | 33.09K | (3.62K) | 3.84K |
| Net Change in Cash | 17.25M | (4.21M) | 4.07M | 172.16K | 76.25M |
| Free Cash Flow | (1.59M) | (7.41M) | (11.42M) | (15.77M) | (24.66M) |
Immix Biopharma, Inc.
NASDAQ:IMMX
Intrinsic Alpha fair value
Locked
Current Price
$7.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.